Welcome Guest | Register / Login

Alzheimer's Disease Patients & Market Worldwide, Future Scenario (2010 - 2015) & Drugs Analysis

Table of Contents

1. Executive Summary

2. Worldwide Prevalence of Alzheimer’s Patients
2.1 Total Number of Alzheimer’s Patients
2.2 Total Number of Early Stage Alzheimer’s Patients
2.3 Total Number of Late Stage Alzheimer’s Patients

3. Regional Estimates for Alzheimer’s Patients
3.1 Africa
3.1.1 Total Number of Alzheimer’s Patients
3.1.2 Total Number of Early Stage Alzheimer’s Patients
3.1.3 Total Number of Late Stage Alzheimer’s Patients
3.2 Asia
3.2.1 Total Number of Alzheimer’s Patients
3.2.2 Total Number of Early Stage Alzheimer’s Patients
3.2.3 Total Number of Late Stage Alzheimer’s Patients
3.3 Europe
3.3.1 Total Number of Alzheimer’s Patients
3.3.2 Total Number of Early Stage Alzheimer’s Patients
3.3.3 Total Number Of Late Stage Alzheimer’s Patients
3.4 Latin America & Caribbean
3.4.1 Total Number of Alzheimer’s Patients
3.4.2 Total Number of Early Stage Alzheimer’s Patients
3.4.3 Total Number of Late Stage Alzheimer’s Patients
3.5 North America
3.5.1 Total Number of Alzheimer’s Patients
3.5.2 Total Number of Early Stage Alzheimer’s Patients
3.5.3 Total Number of Late Stage Alzheimer’s Patients
3.6 Oceania
3.6.1 Total Number of Alzheimer’s Patients
3.6.2 Total Number of Early Stage Alzheimer’s Patients
3.6.3 Total Number of Late Stage Alzheimer’s Patients

4. Worldwide Alzheimer’s Disease Market
4.1 North America Alzheimer’s Disease Market
4.2 Europe Alzheimer’s Disease Market
4.3 Rest of the World Alzheimer’s Disease Market

5. Worldwide – Alzheimer’s Drug Market Share 2008 – 2009

6. Worldwide – Top 10 Alzheimer’s Drug Brands Market Performance
6.1 Exelon (Rivastigmine) – Past, Present & Future Forecast
6.2 Aricept (Donepezil) – Past & Present Market
6.3 Razadyne (Galantamine) (Past & Present Market)
6.4 Memantine (Namenda, Ebixa, Axura)
6.4.1 Namenda (Memantine) – Past, Present & Future Forecast
6.4.2 Ebixa (Memantine) – Past, Present & Future Forecast
6.4.3 Axura (Memantine) – Past, Present & Future Forecast
6.5 Nootropil (Piracetam) – Past, Present & Future Market
6.6 Prometax (Rivastigmine) – Past, Present & Future Forecast
6.7 Memac (Donepezil)
6.8 Eranz (Donepezil)
6.9 Future Blockbuster Alzheimer’s Drug

7. Alzheimer’s Disease Deals, 2005 – 2009

8. Key Drivers of Growth in Global Alzheimer’s Disease Drug Market
8.1 Aging Population
8.2 Unmet Medical Needs
8.3 Future Drugs for Disease Modification in Alzheimer’s Disease

9. Key Challenges in the Global Alzheimer’s Disease Drug Market
9.1 Lack of Validated Targets & Lack of Animal Models
9.2 Barriers in the Design and Implementation of Clinical Trials
9.3 Barriers in Academia & Regulatory Issues

10. Key Players in the Alzheimer’s Drug Market
10.1 Forest Laboratorie
10.2 Eisai
10.3 H. Lundbeck A/S
10.4 Novartis
10.5 Merz GmbH & Co. KGaA
10.6 Johnson & Johnson
10.7 UCB

List of Tables

Table 2 1: Worldwide – Forecast For Number of Patients with Alzheimer’s (Million) 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
Table 2 2: Worldwide – Stages of Alzheimer’s Disease
Table 2 3: Worldwide – Forecast for Number of Patients with Early Stage Alzheimer’s Disease (Million) 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
Table 2 4: Worldwide – Forecast for Number of Patients with Late Stage Alzheimer’s Disease (Million), 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
Table 3 1: Africa – Forecast for Number of Patients with Alzheimer’s Disease (Million), 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
Table 3 2: Africa – Forecast for Number of Patients with Early Stage Alzheimer’s Disease (Million), 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
Table 3 3: Africa – Forecast for Number of Patients with Late Stage Alzheimer’s Disease (Million), 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
Table 3 4: Asia – Forecast for Number of Patients with Alzheimer’s Disease (Million), 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
Table 3 5: Asia – Number of Patients with early stage Alzheimer’s Disease (Million), 2006 – 2010
Table 3 6: Asia – Forecast for Number of Patients with Early Stage Alzheimer’s Disease (Million), 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
Table 3 7: Asia – Forecast for Number of Patients with Late Stage Alzheimer’s Disease (Million), 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
Table 3 8: Europe – Forecast for Number of Patients with Alzheimer ’s Disease (Million), 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
Table 3 9: Europe – Forecast for Number of Patients with Early Stage Alzheimer’s Disease (Million), 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
Table 3 10: Europe – Forecast for number of patients with late stage Alzheimer’s Disease (Million), 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
Table 3 11: Latin America & Caribbean – Forecast for Number Of Patients with Alzheimer’s Disease (Million), 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
Table 3 12: Latin America & Caribbean – Forecast for Number of Patients with Early Stage Alzheimer’s Disease (Million), 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
Table 3 13: Latin America & Caribbean – Forecast for Number of Patients with Late Stage Alzheimer’s Disease (Million), 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
Table 3 14: North America – Forecast for Number of Patients with Alzheimer’s Disease (Million), 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
Table 3 15: North America – Forecast for Number of Patients with Early Stage Alzheimer’s Disease (Million), 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
Table 3 16: North America – Forecast for Number of Patients with Late Stage Alzheimer’s Disease (Million), 2011 – 2016, 2020, 2025, 2030, 2035, 2040, 2045, 2050
Table 3 17: Oceania – Forecast for Number Of Patients with Alzheimer’s Disease (Million), 2011 – 2016, 2020, 2025, 2030, 2035, 2040, 2045, 2050
Table 3 18: Oceania – Forecast for Number of Patients with Early Stage Alzheimer’s Disease            (Million), 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
Table 3 19: Oceania – Forecast for Number of Patients with Late Stage Alzheimer’s Disease (Million), 2011 – 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050
Table 6 1: Worldwide – Bapineuzumab Drug Future Forecast Sales, (Billion US$), 2016
Table 7 1: Worldwide – Alzheimer’s Disease Deals, 2005 – 2009
Table 8 1: Worldwide – Population Aged 60 or Over, 65 or Over and 80 Or Over By Sex (Thousands): World, Major Areas and Regions, 2009
Table 10 1: Forest Laboratories – Key Financials (Million US$), March 2008 – March 2010
Table 10 2: Eisai – Key Financials (Million US$) March 2008 – March 2010
Table 10 3: H. Lundbeck A/S – Key Financials (Million US$), 2007 – 2009
Table 10 4: Novartis – Key Financials (Million US$), 2007 – 2009
Table 10 5: Merz GmbH & Co. KGaA – Key Financials (Euro Million) 2007/08 – 2008/09
Table 10 6: Johnson & Johnson – Key Financials (Million US$) 2007 – 2009
Table 10 7: UCB – Key Financials (Million US$) 2007 – 2009

List of Figures

Figure 2 1: Worldwide – Number of Patients with Alzheimer’s Disease (Million), 2006 – 2010
Figure 2 2: Worldwide – Number of Patients with Early Stage Alzheimer’s Disease (Million), 2006 – 2010
Figure 2 3: Worldwide – Number of Patients with Late Stage Alzheimer’s Disease (Million), 2006 – 2010
Figure 3 1: Africa – Number of Patients with Alzheimer’s Disease (Million), 2006 – 2010
Figure 3 2: Africa – Number of Patients with Early Stage Alzheimer’s Disease (Million), 2006 – 2010
Figure 3 3: Africa – Number of Patients with Late Stage Alzheimer’s Disease (Million), 2006 – 2010
Figure 3 4: Asia – Number of Patients with Alzheimer’s Disease (Million), 2006 – 2010
Figure 3 5: Asia – Number of Patients with Late Stage Alzheimer’s Disease (Million), 2006 – 2010
Figure 3 6: Europe – Number of Patients with Alzheimer’s Disease (Million), 2006 – 2010
Figure 3 7: Europe – Number of Patients with Early Stage Alzheimer ’s Disease (Million), 2006 – 2010
Figure 3 8: Europe – Number of Patients with Late Stage Alzheimer ’s Disease (Million), 2006 – 2010
Figure 3 9: Latin America & Caribbean – Number of Patients with Alzheimer’s Disease (Million), 2006 – 2010
Figure 3 10: Latin America & Caribbean – Number of Patients with Early Stage Alzheimer’s Disease (Million), 2006 – 2010
Figure 3 11: Latin America & Caribbean – Number of Patients with Late Stage Alzheimer’s Disease (Million), 2006 – 2010
Figure 3 12: North America – Number of Patients with Alzheimer’s Disease (Million), 2006 – 2010
Figure 3 13: North America – Number of Patients with Early Stage Alzheimer’s Disease (Million), 2006 – 2010
Figure 3 14: North America – Number of Patients with Late Stage Alzheimer’s Disease (Million), 2006 – 2010
Figure 3 15: Oceania – Number of Patients with Alzheimer’s Disease (Million), 2006 – 2010
Figure 3 16: Oceania – Number of Patients with Early Stage Alzheimer’s Disease (Million), 2006 – 2010
Figure 3 17: Oceania – Number of Patients with Late Stage Alzheimer’s Disease (Million), 2006 – 2010
Figure 4 1: Worldwide – Alzheimer’s Disease Market (Billion US$), 2006 – 2010
Figure 4 2: Worldwide – Future Forecast for Alzheimer’s Disease Market (Billion US$), 2011 – 2015
Figure 4 3: North America – Alzheimer’s Disease Market (Billion US$), 2006 – 2010
Figure 4 4: North America – Future Forecast for Alzheimer’s Disease Market (Billion US$), 2011 – 2015
Figure 4 5: Europe – Alzheimer’s Disease Market (Billion US$), 2006 – 2010
Figure 4 6: Europe – Future Forecast for Alzheimer’s Disease Market (Billion US$), 2011 – 2015
Figure 4 7: Rest of the World – Alzheimer’s Disease Market (Billion US$), 2006 – 2010
Figure 4 8: Rest of the World – Forecast for Alzheimer’s Disease Market (Billion US$), 2011 – 2015
Figure 5 1: Worldwide – Drug Companies Market Share in Alzheimer’s Disease Market (Percent), 2008
Figure 5 2: Worldwide – Drug Companies Market Share in Alzheimer’s Disease Market (Percent), 2009
Figure 6 1: Worldwide – Exelon Alzheimer’s Drug Sales (Million US$), 2005 – 2010
Figure 6 2: Worldwide – Future Forecast for Exelon Alzheimer’s Drug Sales (Million US$), 2010 – 2014
Figure 6 3: Worldwide – Aricept Alzheimer’s Drug Sales (Billion US$), 2005 – 2009
Figure 6 4: Worldwide – Razadyne Alzheimer’s Drug Sales (Million US$), 2007 – 2009
Figure 6 5: Worldwide – Namenda Alzheimer’s Drug Sales (Million US$), 2003 – 2010
Figure 6 6: Worldwide – Future Forecast for Namenda Alzheimer’s Drug Sales (Million US$), 2011 – 2015
Figure 6 7: Worldwide – Ebixa Alzheimer’s Drug Sales (Million US$), 2003 – 2010
Figure 6 8: Worldwide – Future Forecast for Ebixa Alzheimer’s Drug Sales (Million US$), 2011 – 2014
Figure 6 9: Worldwide – Axura Alzheimer’s Drug Sales (Million US$), 2003 – 2010
Figure 6 10: Worldwide – Future Forecast for Axura Alzheimer’s Drug Sales (Million US$), 2011 – 2014
Figure 6 11: Worldwide – Nootropil Alzheimer’s Drug Sales (Million US$), 2004 – 2010
Figure 6 12: Worldwide – Future Forecast for Nootropil Alzheimer’s Drug Sales (Million US$), 2011 – 2014
Figure 6 13: Worldwide – Prometax Alzheimer’s Drug Sales (Million US$), 2007 – 2010
Figure 6 14: Worldwide – Future Forecast for Prometax Alzheimer’s Drug Sales (Million US$), 2011 – 2012
Figure 6 15: Worldwide – Memac Alzheimer’s Drug Sales (Million US$), 2007 – 2009
Figure 6 16: Worldwide – Eranz Alzheimer’s Drug Sales (Million US$), 2007 – 2009
Figure 8 1: Worldwide – Population Aged 60 or Over: World and Development Regions, 1950, 1975, 2009, 2025 & 2050
Figure 8 2: Worldwide – Old-Age Dependency Ratio: Major Areas, 2009 & 2050

Why http://www.marketreportsonline.com/
Published By :Renub Research
Price
Live Chat
Live Chat by Comm100